journal article·2024-03-13Open access

Selective Replacement of Cholesterol with Cationic Amphiphilic Drugs Enables the Design of Lipid Nanoparticles with Improved RNA Delivery

Bram Bogaert, Aliona Debisschop, Thomas Ehouarne, Hannelore P. Van Eeckhoutte, Joyceline De Volder, An Jacobs, Eline Pottie, Riet De Rycke, Aurélie Crabbé, Pieter Mestdagh, Ine Lentacker, Guy G. Brusselle, Christophe Stove, Sandra Verstraelen, Tania Maes, Ken R. Bracke, Stefaan C. De Smedt, Koen Raemdonck

Nano Letters· Volume 24· Issue 10

Abstract

The delivery of RNA across biological barriers can be achieved by encapsulation in lipid nanoparticles (LNPs). Cationic amphiphilic drugs (CADs) are pharmacologically diverse compounds with ionizable lipid-like features. In this work, we applied CADs as a fifth component of state-of-the-art LNPs via microfluidic mixing. Improved cytosolic delivery of both siRNA and mRNA was achieved by partly replacing the cholesterol fraction of LNPs with CADs. The LNPs could cross the mucus layer in a mucus-producing air-liquid interface model of human primary bronchial epithelial cells following nebulization. Moreover, CAD-LNPs demonstrated improved epithelial and endothelial targeting following intranasal administration in mice, without a marked pro-inflammatory signature. Importantly, quantification of the CAD-LNP molar composition, as demonstrated for nortriptyline, revealed a gradual leakage of the CAD from the formulation during LNP dialysis. Altogether, these data suggest that the addition of a CAD prior to the rapid mixing process might have an impact on the composition, structure, and performance of LNPs.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Ghent Research Group on Nanomedicines, Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium

Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of Respiratory Medicine, Ghent University Hospital, Ghent University, C. Heymanslaan 10, 9000 Ghent, Belgium

Health Unit, Flemish Institute for Technological Research (VITO), Boeretang 200, 2400 Mol, Belgium

Laboratory of Toxicology, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium

Ghent University Expertise Center for Transmission Electron Microscopy and VIB BioImaging Core, 9000 Ghent, Belgium

Department of Biomedical Molecular Biology, Ghent University, VIB Center for Inflammation Research, 9052 Ghent, Belgium

Laboratory of Pharmaceutical Microbiology, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium

Department of Biomolecular Medicine, OncoRNAlab, Ghent University, C. Heymanslaan 10, 9000 Ghent, Belgium

Funding

Fonds Wetenschappelijk Onderzoek · Bijzonder Onderzoeksfonds UGent · H2020 European Research Council

References (57)

Show source-provided references
1. 10.1038/s41565-019-0591-y10.1038/s41565-019-0591-y ↗
2. 10.1056/NEJMoa203457710.1056/NEJMoa2034577 ↗
3. 10.1056/NEJMoa203538910.1056/NEJMoa2035389 ↗
4. 10.1021/acs.accounts.9b0036810.1021/acs.accounts.9b00368 ↗
5. 10.1038/nrd274210.1038/nrd2742 ↗
6. 10.1038/nrg397810.1038/nrg3978 ↗
7. 10.1038/s41578-021-00358-010.1038/s41578-021-00358-0 ↗
8. 10.1021/acsnano.7b0473410.1021/acsnano.7b04734 ↗
9. 10.1016/j.addr.2022.11441610.1016/j.addr.2022.114416 ↗
10. 10.1039/C9NR09347H10.1039/C9NR09347H ↗
11. 10.1021/acs.accounts.1c0054410.1021/acs.accounts.1c00544 ↗
12. 10.1016/j.ijpharm.2020.11979210.1016/j.ijpharm.2020.119792 ↗
13. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
14. 10.1073/pnas.210925611810.1073/pnas.2109256118 ↗
15. 10.1021/acs.chemrev.7b0067810.1021/acs.chemrev.7b00678 ↗
16. 10.1002/wnan.137710.1002/wnan.1377 ↗
17. 10.1038/s41563-020-00886-010.1038/s41563-020-00886-0 ↗
18. 10.1016/j.jconrel.2017.11.01910.1016/j.jconrel.2017.11.019 ↗
19. 10.1016/j.nantod.2017.06.01210.1016/j.nantod.2017.06.012 ↗
20. 10.1021/acsnano.0c0066610.1021/acsnano.0c00666 ↗
21. 10.1016/j.addr.2021.11404110.1016/j.addr.2021.114041 ↗
22. 10.1016/j.ijpharm.2023.12334810.1016/j.ijpharm.2023.123348 ↗
23. 10.1016/j.jconrel.2022.08.00910.1016/j.jconrel.2022.08.009 ↗
24. 10.1085/jgp.20181226310.1085/jgp.201812263 ↗
25. 10.1016/S0304-4157(00)00012-510.1016/S0304-4157(00)00012-5 ↗
26. 10.1126/sciadv.aaz859810.1126/sciadv.aaz8598 ↗
27. 10.1038/s41565-021-00924-110.1038/s41565-021-00924-1 ↗
28. 10.1021/acsnano.0c1006410.1021/acsnano.0c10064 ↗
29. 10.1038/mt.2010.8510.1038/mt.2010.85 ↗
30. 10.1002/adma.20190612810.1002/adma.201906128 ↗
31. 10.1038/nbt.160210.1038/nbt.1602 ↗
32. 10.1073/pnas.091060310610.1073/pnas.0910603106 ↗
33. 10.1002/anie.20180905610.1002/anie.201809056 ↗
34. 10.1038/ncomms527710.1038/ncomms5277 ↗
35. 10.1038/s41467-022-32281-510.1038/s41467-022-32281-5 ↗
36. 10.1021/acs.nanolett.0c0138610.1021/acs.nanolett.0c01386 ↗
37. 10.1038/s41467-020-14527-210.1038/s41467-020-14527-2 ↗
38. 10.1021/acsnano.8b0364010.1021/acsnano.8b03640 ↗
39. 10.1021/acschembio.5b0075310.1021/acschembio.5b00753 ↗
40. 10.1016/j.bcp.2020.11393410.1016/j.bcp.2020.113934 ↗
41. 10.1021/acs.analchem.9b0310410.1021/acs.analchem.9b03104 ↗
42. 10.1007/s00204-020-02836-w10.1007/s00204-020-02836-w ↗
43. 10.1016/j.jconrel.2015.09.00410.1016/j.jconrel.2015.09.004 ↗
44. 10.1016/j.jconrel.2018.10.01210.1016/j.jconrel.2018.10.012 ↗
45. 10.1016/j.jconrel.2021.11.02310.1016/j.jconrel.2021.11.023 ↗
46. 10.1038/s41587-020-0692-z10.1038/s41587-020-0692-z ↗
47. 10.3390/pharmaceutics1211104210.3390/pharmaceutics12111042 ↗
48. 10.1021/acsnano.2c0564710.1021/acsnano.2c05647 ↗
49. 10.1038/mt.2016.18210.1038/mt.2016.182 ↗
50. 10.1126/sciadv.160155610.1126/sciadv.1601556 ↗
51. 10.1016/j.biomaterials.2008.12.07610.1016/j.biomaterials.2008.12.076 ↗
52. 10.3390/ijms2217921610.3390/ijms22179216 ↗
53. 10.1038/ni.305210.1038/ni.3052 ↗
54. 10.1016/j.jconrel.2022.03.05110.1016/j.jconrel.2022.03.051 ↗
55. 10.3390/nano1108196310.3390/nano11081963 ↗
56. 10.1021/acs.molpharmaceut.1c0049110.1021/acs.molpharmaceut.1c00491 ↗
57. 10.1089/jir.2008.002710.1089/jir.2008.0027 ↗